[{"id":"folr1","kind":"target","name":"Folate receptor alpha","route":"/targets/folr1/","commit":"91a4bba51c","date":"2026-09-10","author":"Jude Gomila","message":"Fourteen orphan products now linked from their targets and cancers (ALK, EGFR, ROS1, ER, FOLR1 inhibitors and tracers; myeloma, prostate, gl","file":"src/data/targets.ts","type":"changed","fields":[{"field":"drugs","after":"[\"pafolacianine\"]"}]},{"id":"folr1","kind":"target","name":"Folate receptor alpha","route":"/targets/folr1/","commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/targets.ts","type":"changed","fields":[{"field":"tldr","before":"\"A vitamin receptor that ovarian cancer cells carry in large numbers, used as the docking site for the ADC mirvetuximab.\"","after":"\"Folate receptor alpha is a vitamin receptor that ovarian cancer cells carry in large numbers, used as the docking site for the ADC mirvetuximab.\""}]},{"id":"folr1","kind":"target","name":"Folate receptor alpha","route":"/targets/folr1/","commit":"cebb34a709","date":"2026-09-08","author":"Jude Gomila","message":"Guideline mapping on every standard-of-care row; sourced biomarker prevalence for 59 targets; GuidelineChip, PrevalenceTable, CancerPrevalen","file":"src/data/targets.ts","type":"changed","fields":[{"field":"prevalence","after":"[\n      { cancerId: \"ovarian\", pct: \"35-40\", measure: \"FRα-high (PS2+ in >=75% of cells)\", source: \"https://en.wikipedia.org/wiki/Folate_receptor_1\", note: \"MIRASOL eligibility; ~80% any expression\" },\n      { cancerI..."}]}]